Cancer immunotherapy has made remarkable clinical advances in recent years. Antibodies
targeting the immune checkpoint receptors PD-1 and CTLA-4 and adoptive cell therapy …

In contrast to its inhibitory effects on many cells, IL10 activates CD8+ tumor-infiltrating
lymphocytes (TIL) and enhances their antitumor activity. However, CD8+ TILs do not …

Complement aids in the construction of an immunosuppressive tumor microenvironment.
Tumor cell–derived C3 has been previously reported, but whether and how it acts on …

Reactivation of cytotoxic CD8+ T-cell responses has set a new direction for cancer
immunotherapy. Neutralizing antibodies targeting immune checkpoint programmed cell …

The impact of complement on cancer metastasis has not been well studied. In this report, we
demonstrate in a preclinical mouse model of breast cancer that the complement …

Among the most promising approaches to activating therapeutic antitumour immunity is the
blockade of immune checkpoints. Immune checkpoints refer to a plethora of inhibitory …

Simple Summary We used multi-omics approaches to evaluate the association of
complement signature C3/C5/C3AR1/C5AR1 with tumor immune phenotypes and prognosis …

Therapeutics that target the T cell inhibitory checkpoint proteins CTLA-4 and PD (L) 1 are
efficacious across a broad range of cancers, resulting in reductions in tumor burden and …

Cancer treatments often reach a refractory period leading to treatment failure and patients
developing disease recurrence. This can be due to tumour cells escaping the immune …

Malignant cells have the capacity to rapidly grow exponentially and spread in part by
suppressing, evading, and exploiting the host immune system. Immunotherapy is a form of …